The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

Matricelf Partners with Japan's CiRA Foundation for Regenerative Medicine Research

Key Facts

1Matricelf (TASE: MTLF) signed a Collaborative Research Agreement with Japan's CiRA Foundation, a leader in iPSC research.

2The collaboration aims to advance next-generation regenerative manufacturing using induced pluripotent stem cells (iPSC).

3Matricelf specializes in developing autologous engineered neural tissue therapy for spinal cord injury patients.

Create Free Account

Matricelf (TASE: MTLF) has officially signed a Collaborative Research Agreement with the CiRA Foundation, a prominent Japanese institution specializing in stem cell research. The partnership focuses on advancing next-generation manufacturing technologies for regenerative medicine using induced pluripotent stem cells (iPSC). By combining Matricelf's proprietary tissue engineering platform with CiRA's expertise, the collaboration aims to enhance treatments for spinal cord injuries. Matricelf is recognized for its work in developing autologous engineered neural tissues, which are critical for patients with severe nerve damage. This strategic move is expected to validate Matricelf's technological capabilities and expand its global research and development footprint. Investors view such high-level academic and industrial partnerships as a positive indicator for the company's long-term growth in the biotech sector.